Home > Healthcare > Medical Devices > Diagnostic Devices > Antimicrobial Resistance Diagnostics Market

Antimicrobial Resistance Diagnostics Market Share

Report ID: GMI12145
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Antimicrobial Resistance Diagnostic Market Share

The global antimicrobial resistance (AMR) diagnostic market is highly competitive, with key players actively innovating to address the escalating AMR crisis. Major companies offer advanced diagnostic solutions, including molecular diagnostics and point-of-care testing. These companies invest significantly in research and development to improve diagnostic accuracy, reduce test turnaround times, and enhance pathogen detection capabilities.

Strategic collaborations and partnerships are common, as companies aim to leverage technological advancements like next-generation sequencing (NGS) and PCR-based assays to expand their product portfolios. Government initiatives and regulatory support further propel market players to develop effective AMR diagnostic tools. Additionally, emerging players focus on regional markets, where the demand for AMR diagnostics is rising, particularly in Asia Pacific and Latin America, as governments there increase investments in healthcare infrastructure to combat AMR.

Antimicrobial Resistance Diagnostic Market Companies

Prominent players operating in the antimicrobial resistance diagnostic industry include:

Abbott Laboratories
Accelerated Diagnostics, USA
Alifax
Bio-Rad Laboratories
BioMerieux
Beckman Coulter
Becton, Dickinson and Company
F. Hoffmann-La Roche
GeneFluidics
Molsid
Thermo Fisher Scientific
Vela Diagnostics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antimicrobial resistance diagnostics industry was valued at USD 4.4 billion in 2023 and is estimated to grow at a 6.3% CAGR from 2024 to 2032, driven by the increasing prevalence of antibiotic-resistant infections.

The kits & reagents segment dominated the market with USD 2.8 billion in 2023 due to their essential role in the early and accurate identification of resistant bacterial strains, which helps reduce inappropriate antibiotic use.

The U.S. antimicrobial resistance diagnostics industry is expected to grow at a 6.2% CAGR, reaching USD 3.1 billion by 2032, supported by government initiatives like CARB and ARSI.

Key players in the industry include Abbott Laboratories, Accelerated Diagnostics, USA, Alifax, Bio-Rad Laboratories, BioMerieux, Beckman Coulter, Becton, Dickinson and Company, and F. Hoffmann-La Roche.